Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating remaining vestibular function prior to surgery, through gentamicin injections in the middle ear.


Clinical Trial Description

The residual function of the vestibular system before surgery differs considerably between patients, due to extent and influence of tumor growth, resulting in varying spectra of post-surgery illness as well as vestibular symptoms. An acute unilateral vestibular deafferentation (uVD) (if significant vestibular function remains prior to surgery) invariably results in severe nausea and vertigo. The nausea/vertigo induced by surgery and sudden uVD both can impede vestibular compensation processes and in extension, also the need for rehabilitation. The vestibular PREHAB protocol was developed in order to address this problem and to ensure an enhanced and sufficient rehabilitation. The protocol encompass treating patients that have measurable vestibular function before surgery with intratympanic gentamicin injections, thus producing gradually a uVD over a period of 3-4 weeks, whilst performing daily vestibular exercises before and after the gentamicin treatment. Through this procedure the sensory trauma is separated from the surgical trauma, making it possible for vestibular compensation to ensue as the vestibular function gradually decline from gentamicin toxicity, unencumbered by any depression of central nervous function that might result from schwannoma surgery or the acute stages of an uVD. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02379754
Study type Interventional
Source Lund University
Contact
Status Withdrawn
Phase Phase 4
Start date January 2015
Completion date September 2020

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT04351373 - Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Phase 2
Active, not recruiting NCT01449604 - Stereotactic Radiation in Vestibular Schwannoma Phase 3
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Not yet recruiting NCT05567341 - Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery N/A
Completed NCT02249572 - Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. N/A
Terminated NCT05116878 - Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma N/A
Suspended NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT04801953 - Nimodipine in Vestibular Schwanommas Phase 2
Recruiting NCT03745560 - Intraoperative EABR for Decision Making
Recruiting NCT04859335 - Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma N/A
Recruiting NCT04128345 - Novel Multimodality Imaging for Navigation in Skull Base Surgery
Active, not recruiting NCT01199978 - Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Phase 2
Recruiting NCT04057976 - Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas N/A
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Recruiting NCT05786144 - Vestibular Schwannoma Organoids
Recruiting NCT03593577 - Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI